Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
NCT00439296 · Therapeutic Advances in Childhood Leukemia Consortium · PHASE1/PHASE2 · terminated · last registry update 2021-03-17 · Childhood acute lymphoblastic leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was stopped due to poor accrual and lack of funding.” | – | Registry record, Therapeutic Advances in Childhood Leukemia Consortium |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TUBB4B in childhood acute lymphoblastic leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-02-23Results posted on the registry: National Cancer Institute (NCI), Bortezomib + Cyclophosphamide (NCT02112916)
- 2021-04-13Results posted on the registry: M.D. Anderson Cancer Center, Cyclophosphamide + Cytarabine (NCT03488225)
- 2020-08-28Phase 3 first posted: National Cancer Institute (NCI), Blinatumomab + Cyclophosphamide (NCT04530565)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision